IJBPAS, March, 2022, 11(3): 986-1006

ISSN: 2277–4998

International Journal of Biology, Pharmacy and Allied Sciences (IJBPAS)

'A Bridge Between Laboratory and Reader'

www.ijbpas.com

PARKINSON'S DISEASE: A REVIEW BASED ON GENES INVOLVED

MAL YK, KUMAR R, KHURANA N, SHARMA N AND KUMAR R*

School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India, 144411

***Corresponding Author: Dr. Rajan Kumar: E Mail: rajankumar2788@gmail.com, rajan.26188@lpu.co.in**

Received 13th April 2021; Revised 16th May 2021; Accepted 14th June 2021; Available online 1st March 2022

https://doi.org/10.31032/IJBPAS/2022/11.3.5922

ABSTRACT

Parkinson disease introduced to the category of neurologic diseases which can cause the motion issues similar to the PD, for example brady-kinesia, resting shaking, rigidity and another is the flexed structure, "freezing," and lack of the postural reflexrs. PD is the steadily progressing Parkinsonism syndrome which can affect the one part of the body and then spread to other part of the body. In a sub-stantianigra pars Compacta, the pathologic loss of the neuromelanin contained the mono-amine neuron, especially DA neurons in the existence of the cytoplasmic eosinophilic inclusion in the mono-amine neurons is the pathology trademark. A hereditary basis of the unusual Parkinson's disease types of the Mendelian inheritance, which account for less than the 10 % of the cases have been studied over the last decennium. Do far more than sixteen loci and eleven associated genes have been discovered with the genome wide association studied demonstrating the polymeric variations in these genes play a role in the sporadic Parkinson's disease. A understanding of the roles of their protein product has shown the neuro-degeneration mechanisms that might be common to both hereditary and the sporadic Parkinson's disease. The key tasks of the next decennium will be to strength these findings and then find another convergence point by discovering the new genes responsible for the Mendelian types of the Parkinson's disease and exploring their roles and relationships. In this study we attempt to summarize the available knowledge on the main genes which are involved in the Parkinson's disease.

Keywords: Parkinson's disease, neuro-degeneration, Parkinsonism syndrome

INTRODUCTION

The Parkinson's disease is a long term and continuous motion disorder, the one whose indication steady and become worsen over time. Around the 1 million population in the United states are patients of PD. The origin of this disease is not known, and while at present there is not any treatment for the Parkinson disease (PD), some treatment options are there for e.g medicines and surgery to control its manifestations. This PD cause the demise of some necessary nerve cells in the brain call as neurons and involved in malfunction. Parkinson's primarily affects neurons in the area of the brain called the substantianigra **[1]**. These kind of expiring neurons generate DA, a toxin that communicates with the region of the brain which regulates the motion and function. The quantity of dopamine generated in the brain reduces as PD progress, exiting an individual unfit to regulation motion normally.

Shaking, rigidness, hypokinesia and posture un-stability are the 4 major indications of PD. Shaking is defined as an in-voluntary motion of the hand, arms, lower body or jaw. Rigidness refers to a in-felxibility arms and legs although hypokinesia refers to the slowdown of motion. Some side effects are anxiety, mood swings, deglutition, chewing and talking difficulties, bladder infections or diarrhea, skin issues and sleep disturbances **[1]**.

The identification is predicated on the medical record and neuro-logical inspection organize by inter-viewing and distinguish the person using the UPDRS **[2]**. Leading to the creation of the unified Parkinson's disease rating scale numerous measurements have been used in different venues, such as the Webster and the Columbia and king's college, North-western university disability and the New York University Parkinson's Disease Scale and University of California at Los Angeles Rating Scales **[3]**.

To quick changes that occur throughout the field of medical decision making support systems are extremely essential. Massive data binaries, such as hospitals, use data centre and data extract idea to withdraw the meaningful details. Data drilling is described as non-trivial removal from the data of implied, newly discovered, and particularly effective details. Just 75% of medical conditions of PD are verified for being idiopathic PD at necropsy because of manifestation overrun with extra disorders **[2]**. Category methods could also aid in increased the validity and consistency of detection and also reducing the potential defects treatment extra time saving **[4]**.

HISTORY OF PARKINSON'S DISEASE

Incredibly, James Parkinson authored a research paper explaining the reality that bears his title or name that same year, 1817, also the New York University of fields of science was started **[5]**. He reported 6 people who had the clinical characteristics. The person has been followed in depth throughout a prolonged duration of time, the another 5 were key examples, such as 2 people he met while walking down the road and the other person he saw from a distance. These remote measurement without some kind of medical examination illustrates how clearly recognisable the situation is based solely on patients personality of flexed stance, psychogenic tremor and stumble gait. "Unintentional shivering movement with minimize muscle strength, in the body parts not in activity and equality though stand up for with the proclivity to curve body upward and to move from such a trying to walk to a jogging pace, the sensation and brain power bring unaffected." Even through the limited group of patient's studied, the Parkinson demonstrated the significance of the manifestations as well as a discussion of the disease's continuing worsening, that he referred to as trembling palsy although by Latin word paralysis agitans.

In his monograph, Parkinson reviewed the different kinds of tremors previously reported and specifically cited the tremor in his "An Essay on the Shaking Palsy" as occurring when the body part is at rest and not during an active voluntary movement **[6]**.

The term paralysis and palsy in paralysis agitans and shaking palsy are also in-appropriate. There is no true paralysis. Today, the "lessened muscular power" mentioned by Parkinson is recognized to be a slowness of movement that is called akinesia, hypokinesia, or bradykinesia, all three terms often being used interchangeably. These terms represent a paucity of movement in the absence of weakness or paralysis.

Sluggishness was linked to rigidness by Charcot throughout the Charcot's Tuesday sessions of 1888 and the fatigue was expressly omitted as a source. PD was characterized by Gower's in 1893 **[7]** as shaking, enervation, rigidness, flexed position, shot stride with sluggishness partly caused by rigidness. In the year of 1911 **[8]**. Oppenheim suggested that even in the absent of rig, weakness and retardation of functional motions could happen. The particular difficulties in inception of motion mostly as the function of sluggishness was stated by Wechsler in the year of 1932 version of his book **[9]**. Wilson was using the three words

akinesia (palsy or paralysis), akinesia, hypokinesia in Wilson massive nerve system opus of 1940 **[10]**. He described the ulterior droop, the courageous eyes, in which the lack of motions and patient seated motionless in such conditions. In the year of 1959 **[11]** three members Schwab, England, Peter-son dedicated the whole article to the topic of akinesia or palsy and by which this occasion had been vigorously located as the " decrease muscular ability" introduced by parkimson.

PATHOPHYSIOLOGY OF PARKINSON'S DISEASE

The type trademark of PD **[12]** and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produce Parkinson's disease **[13]** is the deterioration of dopamine cell with-in the substantia nigra which results in the successive DA consumption of the striatal. The ultimate specified symptom of idio-pathic PD is rest-tremor **[14-16]**. People with tremor ruling PD have such a greater development regarding disorder development than someone with the a-kinetic or the inflexible variation **[17, 18]**. So many research has found that pathophysiology of living beings shaking Parkinson's disease varies from those of the a-kinesia and the rigid dominance Parkinson's disease. The central substantia nigra particularly the retro-rubralregion A eight is much more seriously impacted by dopamine receptor cell deterioration in shaking dominance shape, whereas the sideways substantia nigra A nine has been much seriously weakened in the a-kinetic or the inflexible variation **[15, 19, 20]**.

EPIDEMIOLOGY

Even though Parkinson's disease could affect anyone at any age, this is the most common among the old age people's with such a maximum age of onset of approximately sixty years. The risk of suffering Parkinson's disease enhances dramatically with such a life danger of around 2% **[21]**. A favourable household background raises the danger of Parkinson's disease by around 4%. According to the twin research, Parkinson's disease that begins before the age of fifty years has a higher chance of being genetically linked than the Parkinson's disease which begins older age **[22]**. Men possess a excessive frequency of occurrence and the ubiquity than women. People suffering with Parkinson's disease could survive for twenty years or may be longer, depends on their age at start. The death scale is nearly 1.6 times higher than that of healthy people which are the same age group **[23]**. The symptoms of reduced movement, aspirations, enhanced falls with resulting

physical harm are all common causes of the death in people with having Parkinson's disease. Estimated with the 850,000 people currently have Parkinson's disease, also with the numeral estimated to rise as that of the community ages.

Table 1: Available drug therapy fro Parkinson's disease [24]

S. No.	CLASS OF DRUGS	NAME OF DRUGS	MECHANISM OF DRUGS	SIDE EFFECTS
1	Dopamine precursor	Levodopa (L-dopa)	Once levodopa crosses the blood-brain barrier it is converted to dopamine. Then increase in brain concentration is DA to improve nerve conduction & assist the movement disorders in Parkinson	Nausea, vomiting Cardiac arrhythmias, Abnormal movement (dyskinesias)
2	Peripheral decarboxylase Inhibitors	Carbidopa Benserazide	Carbi-dopa operates by blocking the breakdown of L-DOPA until it enters the brain	Involuntary movements, postural Hypotension, Behavioural abnormalities
3	Dopaminergic agonists	Bromcriptine Roprinirole Pramipexole	Bromocriptine, aDA agonist, that inhibit the pituitary prolactin secretion by binding to the DA receptors	Vomiting, nasal stuffiness, hallucinations, hypotension
4	MAO-B Inhibitor	Selegiline Rasagiline	Rasagiline prohibit the degradation of DA by binding to Monoamine oxidase-B in an irreversible manner	Postural hypotension, Nausea, Confusion, Involuntary movements, dyskinesia, vomiting
5	COMT Inhibitors	Entacapone Tolcapone	Enta-capone is thought to affect the pharma-kinetics of L-DOPA in the blood streaming by inhibiting Catechol-O-Methyltransferase in peripheral tissues	Nausea, vomiting, dyskinesia, postural hypotension, hallucinations,
6	Glutamate (NMDA receptor) antagonist (Dopamine facilitator)	Amantadine	It interferes with the release of infectious viral nucleic acid into the host cell through interaction with the transmembrane domain ofthe M2 protein of the virus	insomnia, restlessness, confusion, nightmares.

Table: Drugs affecting cholinergic system

S. No.	CLASS OF DRUG	NAME OF DRUG	MECHANISM OF DRUG	SIDE EFFECTS
1	Central Anticholinergics	Trihexyphenidyl (Benzhexol), Procyclidine, Biperiden.	A competitive anta-gonist of Ach at choli-nergic receptors in the corpus striatum is thought to be related to centrally active anti-cholinergic drugs like biperiden which restore the balance	Impairment of memory, organic confusional states and blurred vision.
2	Antihistaminics	Orphenadrine, Promethazine.	The mesolimbic dopamine receptors and the Alpha-adrenergic receptors in the brain are also directly antagonistic to promethazine. As an H1 receptor, itshowsanti-histamine properties	Dizziness, headache, loss of appetite, nausea.

GENETICS INVOLVE IN PARKINSON'S DISEASE

The effects of inherited considerations in Parkinson's disease has become the subject matter of the extensive research since Gower's genuine remark that estimated the 15% of the his Parkinson's disease patients described an influenced the family member **[25]**. To dating site, alterations in numerous genetic variants for e.g. (a-synuclein and the another one is parkin and nuclear receptor related 1) and these were detected as being reasonable for occasional household regions of the disorder and the another site have been linked. The parkin chromosome is essential in both slightly earlier household Parkinson's disease except the lewy bodies and the sporadic Parkinson's disease **[26]**.

The majority of people with Parkinson's disease, on the other hand have a intermittent disorder with the complicated aetiology caused by the correlations with the social factors and hereditary makeup. There will be pair of manners that are commonly used to identify the Parkinson's disease vulnerability genes. The one would be focused on the use of non-parametric techniques for detecting genes linking by the use of unintended genes screening such studies have connected Parkinson's disease to genes on chromosomes for e.g. IIp, IVq XXI-XXIII, V, XIII, X **[27]**, X, VIIq, VIIIp and some other chromosomes are Vq, VI, IXq **[28]**. The possible genes method which is focused on the perception of the physiology of Parkinson's disease, is the another choice **[29]**.

CAUSATIVE GENES OF INHERITED PARKINSON'S DISEASE

Alfa-Synuclein: In such a big italic and USA familial with auto-somal potent initial start of Parkinson's disease the 1stgene was discovered [30].The mis-sense variation A-53T in the axon four in the genes coding a a-synuclein has been recognized and then linked to the marked on chromosomes for e.g. IVq XXI-qXXIII. a-synuclein had also discovered in influenced people's of the three Greek households with the Parkinson's disease **[31]** then the cellule localisation researches manifest that this a-synuclein irregular credited in the Lewy body, the main pathology trademark of the idio-pathic Parkinson's disease **[32]**. Then in the tiny Germany familial with the Parkinson's disease the 2nd variation (A30P) was discovered **[33]**. In recent a 3rd variation (E46K) was discovered in a Spain household **[34]**, as well as the a-synuclein gees triplicate in 2 separate households **[35, 36]**. These all findings suggest that variations or enhance in the quantity of cellule a-synuclein is essential

for the pathogenic of Parkinson plus disorders.

It is a one fourth amino acid solvable protein that is copious in the neuron and then particularly focused in the pre-synaptic terminal. It's work is not known. The a-synuclein related proteins are found in a number of proteins **[37]**.

Synphilin-1:-for e.g. as a-synuclein, synphilin-one is as well elongated in the neuron and co-immunoprecipitate with the synaptic vesicles **[38]**.

2. Tubulin **[39]**.

3. Micro-tubule concerned protein tau **[40]**. The interlinkage in the middle of the a-synuclein and tau canrelate synaptic vesicles with the micro-tubules.

4. Unphos-phorylated TH, a-synuclein joining reduces cellule DA contented through prohibiton of tyrosine hydroxylase activity **[41]**.

The lipoid linking is carried out by the 102 & 103 amine or N-terminal residue of the a-synuclein **[42]**. In the non- attendance of the lipids the a-synuclein have a restricted shape but in the appearance of the phospholipid this acquired a helical shape **[43]**.

Parkin

ARJP is a approximately uncommon condition which have before time arrival (It should be prior to the period of forty years) a long diagnostic procedure spanning decagons, and a lack of a DA neuron in the abdominal sub-stantianigra except from the lewy bodies at necropsy for e.g. Autosomal recessive juvenile parkinsonism also have the single method of twin pathology features of idio-pathic Parkinson's disease. In Japan people's Autosomal recessive juvenile parkinsonism infected person with the VIq can collation of the firm lyrelated mark D6S305 unsociable a gene called the parkin **[44, 45]**. Almost half of infected persons with the Autosomal recessive juvenile parkinsonism have the homozygous parkin variations, then about five percent of younger adults with Parkinson's disease have them **[46]**. In the national center for biotechnology information data-bases the above one thousand sole nucleotides variations was discovered so far. Few of the parkin genes poly-morphism have been shown to be unrelated to the Autosomal recessive juvenile parkinsonism or the idio-pathic Parkinson's disease **[47]**, whereas hetero-zygous parkin variations are thought to be responsiveness alleles. Because of a alterable functions lowering in the parkin gene certain variations in the axon seven in parkin gene for e.g. Arg256Cys then Asp280Asn, Cys253Trp and another one is Cys253Trp and Asp275Trp these are

particularly biased to belated onset type of Parkinson's **[48]**.

Four substrates for the ubiquitin-ligase function of parkin have been identified so far:

1. The 22-kDa glyco-sylated form of the a-synuclein **[49]**.
2. Parkin-linked endo-thelin receptor-like receptor, which is associated to endoplasmic reticulum stress and celldeath **[50]**.
3. CDCrel-1, a protein involved in cytokinesis that might influence synaptic vesicle function **[51]**.
4. Synphilin-1 **[52]**.

Various loci along with gene previously linked to Parkinson's disease in genome in broad scan or the applicant genes studies have never shown to be pathogenic. Considering it encrypt the neurons essential component of the household of deubi-quitinating enzyme which cleaves the poly-meric ubiquitin group in the monomer then it is as well present in the Lewy-body, ubiquitin carboxyl-terminal hydrolase isozyme L1 at position of Parkinson'sdisease autosomal dominant 5 locus occurred to be strong Parkinson's disease contender genes. The hetero-zygous one hundred ninety three million disease associated variation within the code succession of the genes which was inaugurate influenced by the subset **[53]**. The variations produce the fifty percent reduction within the hydro-lytic action of enzymes in-vitro **[53, 54]**. Meanwhile a standard poly-morphism with in the ubiquitin carboxyl-terminal hydrolase isozyme L1 gene, the another S18y variation have controversy related to the reduction danger of the idio-pathic Parkinson's disease in various researches, with addition an outsized meta-analysis.

HTRA serine peptidase 2 is a mitochondrial found in the Parkinson's disease13 , it is something else strong contender genes for the Parkinson's disease, with the in-vitro and in-vivo proofs supporting it's pathogenicity **[55-57]**. The hetero-zygous G399S variation was observed in the 4 Germany Parkinson's disease infected persons, although this was observe in the similar level in both the infected persons and regulates in different researches, implying that is an uncommon mutation in the Germany individuals **[58, 59]**. In the another research **[60]**, a A141S replacing in the HTAR2 that was found to be substantially the above representation in a category of the Parkinson's disease infected persons, although none in the further people's **[58, 59]**. There is still no proof that HTAR2 causes Parkinson's disease.

Parkinson 2 variations take place as the most common well known reason of the before time onset within the patients having age between fourty-fifty years Parkinson's disease about ten to twenty percent in world fifty percent (50%) of the recessive household variants, around fifteen percent of lonely cases are found in the Europe individuals **[61, 62]** and this disease was observed in the variety of families of various racial back-grounds **[63]**. A prevalence of the parkin variations towards other hand reduction dramatically with the rising age at disorder, along with 80% of people's which are diagnosed ahead the age of twenty years having parkin variations. This is the extremely unique among those who develop this after the age of the fifty years **[61, 62, 64, 65]**. Axonic removals of the parking genes were firstly discovered in the Japan households with the ARJP **[66]**; including onset occuring often ahead of the person's age of twenty years.A sufferers responded well to the l-DOPA yet they elevated dys-kinesias as the result of it. Above one seventy variations ,includes massive removal or multi-plication, minor removal or interject and misses variations, have since been discovered in the succession of this especially larger gene (1.35 Mb)

Pink1

Three cognate households accompanied by auto-somal recessive before time onset Parkinson's disease are found to have homo-zygousG309D misses and W437X lack of means variations occur in PINK1 genes, which had formerly been related to the PARK6 on the chromosome 1p35-36 **[67, 68]**. PTEN- induced kinase1 non-functional variations, both homozygous and combination heterozygous these are the 2ndleading reason of the autosomal recessive before time onset parkinson, with variation frequencies ranging from the zero to fifteen percent in the whole world **[69, 70]**. The majority of PTEN- induced kinase1 variations are the point variations, minor placing or removal that can be detected by the sequencing, However genomic removals are identified as well as a major removal of the entire gene and the complicated long reordering **[71, 72]**, Indicating the value for gene dose form analysis in the conjunction along with the sequencing for responsive variation mirroring. Variations in the PTEN-induced kinase1 gene are also an uncommon reason of the intermittent before time onset Parkinson's disease **[73, 74]**.

While peoples suffer with PTEN- induced kinase1 variations have the exceptional acknowledgment to the L-DOPA, lesser serious disorder and the long term disorder

periods, a figurativepheno-type of the PTEN-induced kinase1 associated Parkinson's disease occurred as largely alike to the parkin or protein deglycase (DJ1) associated disease **[75]**. Interestly, appearance of the dystonia on the start of brisk reflexes, that were once thought to be characteristic of the parkin carrier, PTEN-induced kinase1 variations tend to be more common in infected persons. Furthermore few evidence suggests that infected persons with PTEN-induced kinase1 variations have such an early disorder onset then more over a-typical manifestations, for e.g. a dystonia at the onset, hyper-reflexia and one is the dys-kinesias then a high incidence of psychiatric disruptions **[76-79]**. Parkin and PTEN- induced kinase1 have been shown to have di-genic legacy in the asian citizens, which may be linked to the psychiatric diseases **[80]**.

DJ-1

Protein deglycase (DJ1) genes variations are less usual reason of the auto-somal recessive Parkinson (occuring for just the 1% of before time onset Parkinson's disease). Protein deglycase (Dj1) at Parkinson 7 was firstly found in 2 cognate households from the Netherland and Italian peoples with the significant homo-zygous removal and a homo-zygous misses variation, L166P **[81]**. A protein deglycase (DJ1) associated with pheno-type accompanied by before time onset and sluggish disorder progress, that is similar to such of peoples suffer with parkin or PTEN-induced kinase1 variations. By the way because of the limited no. of the DJ-1 sufferers, geno-type or pheno-type connections cannot be done significantly. A appearance of the hetero-zygous variations in protein deglycase (DJ1) and the PTEN-induced kinase1 genes in 2 of the China familial members which evolved Parkinson's disease in their age of thirty (30) suggests that di-genic legacy, although it was not entirely penetrated as the fourty two year old brother or sister with alike geno-type was uninfluenced **[82]**.

Protein deglycase (DJ1) was first discovered in a rat , where it was linked to the onco-genesis and the male non-fertility. It belongs to the Thin or Pfp1 familial of the molecule chaperones that are activated in response to the oxidation stress. The human protein deglycase (DJ1), such as the other individuals of the GAT big family have the cysteine at pole position 106 that is strongly conserved. Protein deglycase(DJ1) is the chaperone behaviour tends to be the influenced by the oxidized form of the Cys-106 residue. A production of the sulfonic acid of the Cys-106 the far more susceptible residuum to the oxidation stress, is induced

by the oxidized circumstances **[83]**. This protein deglycase DJ1 transfer from the cytoplasm to the outside mitochondrial membrane in the appearance of the oxidized tension and is believed to take part in the neuro-protection **[84]**.

LRRK2

In the words of prevalence, leucine- rich repeat kinase(LRRK2), which was freshly add on to the category of Parkinson's disease caused genes, it is the most significant. The Parkinson 8 gene was discovered in the larger Japan population, the Saga-mihara family, who had the autosomal commanding un-symmetrical l-DOPA responsive after time onset in the Parkinson's disease **[85]**, then this was later committed in various Europe households **[86]**. Positioning cloning detected various misses variations in the long genes, LRRK2 by 2 separate parties leucine-rich repeat kinase 2 **[87, 88]**. As long as leucine-rich repeat kinase 2 variations are common and observed in the infected persons with the typical after time onset households and the sporadic Parkinson's disease, this finding was possibly the most significant stride onwards in our understanding of the pathogenic of the Parkinson's disease as well as the finding of synuclein alpha. As well as the firstly leucine-rich repeat kinase 2 variations was identified in the Basque household with shaking is the presented then firstly pre-dominant manifestations then the encoded protein has been dubbed "Dardarin" after the Basque term "dardara", which means shaking or tremor **[87]**.

A Leucine-rich repeat kinase 2 G2019S variation is found often in the sporadic cases then various inherited types of the Parkinson's disease with the ambiguous legacy pattern **[89]** as well as in a small number of the controlled ,includes people over the eighty years old **[90]**. Although the ensured bias might justify the broad reach of approximates in these researches, the uneven representation of the households with the multiplication affected people's could leading to the over-estimation of the penetrance **[91]**. According to a new analysis of an unallocated group of infected individuals from the north-africa and the entrance at the age of eighty may be as less as 14% **[92]**. Identification of the hereditary or the atmosphere factor that modulate the entrance in these households would be of the specific interest.

Persons suffer with G2019S variation have the clinical characteristics that are the strikingly similar to those of the individual suffer with another leucine-rich repeat kinase 2 variations or the idio-pathic Parkinson's

disease. The average age of the onset is about sixty years old with the unilateral shaking as the first symptom a strong reaction to the treatment and the steady progress **[93]**.

Apart from synuclein alpha multiplier there has been no evidence of the gene dosage result for leucine-rich repeat kinase2 the thirty homo-zygous variation carrier found so far, mainly among the north-africaArabs, are identical to those with the hetero-zygous variations **[94-96]**. The presence of the stable monitor (at age of 41) and then 3 unaltered relatives (ages 42, 45 and 70) with the homozygous G2019S variations, as well as a 52 year old the unaltered carriers of the heterozygous parkin leucine-rich repeat kinase 2 and glucocerebrosidase (GBA) variations, confirms the leucine-rich repeat kinase 2 decreased the penetrance **[94, 95, 97]**.

CONCLUSION

Parkinson's disease is a neurodegenerative disorder during which there is imbalance occurs between the level of dopamine and acetylcholine. Which, further leads to the development of various symptoms like: tremors, rigidity etc. the available drug therapy only provdes the symptomatic relief to the patients but not able cure the underline pathology. But other reason for not developing cure for PD is large number of genes involved in its progression. Now, few of the genes are identified which are in direct link with the PD. The information which is available regarding the genes involved in the PD can be used near future to develop some therapy for the management of the PD.

REFERENCES

[1] Parkinson's Disease Foundation, http://www.pdf.org/en/about_pd, (2011.09.16).

[2] Ene, M. (2008). Neural network-based approach to discriminate healthy people from those with Parkinson's disease. Annals of the University of Craiova-Mathematics and Computer Science Series, 35, 112-116.

[3] National Institute of Neurological Disorders and Stroke, http://www.ninds.nih.gov/disorders/parkinsons_disease/detai_parkinsons_disease.htm, (2011.09.16).

[4] Gil, D., & Manuel, D. J. (2009). Diagnosing Parkinson by using artificial neural networks and support vector machines. Global Journal of Computer Science and Technology, 9(4).

[5] PARKINSON, J. 1817. An Essay on the Shaking Palsy. Sherwood, Neely, and Jones. London.

[6] Lellouch, A. (1989). Charcot the Clinician. The Tuesday Lessons. Excerpts From Nine Case Presentations

on General Neurology Delivered at the Salpêtrière Hospital in 1887-88.

[7] Gowers, W. R. (1887). A manual of diseases of the nervous system. The Journal of Nervous and Mental Disease, 14(2), 123-125.

[8] OPPENHEM H 1911. Textbook of Nervous Diseases for Physicians and Students, 5th edit., trans, by H. Bruce: pp. 1301-1302. Otto Schulze. Edinburgh.

[9] "WtCHSLER, I.S. 1932. A Textbook of Clinical Neurology, 2nd edit.: p. 576. W.B. Saunders. Philadelphia.

[10] Ilsonn S A.K. . Neurology, vol. H: p. 793. Williams & Wilkms. Baltimore.

[11] Schwab, R. S., England, A. C., & Peterson, E. (1959). Akinesia in Parkinson's disease. Neurology, 9(1), 65-65.

[12] Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., &Seitelberger, F. (1973). Brain dopamine and the syndromes of Parkinson and Huntington Clinical, morphological and neurochemical correlations. Journal of the neurological sciences, 20(4), 415-455.

[13] Pifl, C., Schingnitz, G., &Hornykiewicz, O. (1991). Effect of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience, 44(3), 591-605.

[14] Rajput, A. H., Rozdilsky, B., &Ang, L. (1991). Occurrence of resting tremor in Parkinson's disease. Neurology, 41(8), 1298-1298.

[15] Paulus, W., &Jellinger, K. (1991). The neuropathologic basis of different clinical subgroups of Parkinson's disease. Journal of Neuropathology & Experimental Neurology, 50(6), 743-755.

[16] Deuschl, G., Krack, P., Lauk, M., &Timmer, J. (1996). Clinical neurophysiology of tremor. Journal of clinical neurophysiology, 13(2), 110-121.

[17] Jankovic, J., McDermott, M., Carter, J., Gauthier, S., Goetz, C., Golbe, L., & Parkinson Study Group. (1990). Variable expression of Parkinson's disease: A base-line analysis of the DAT ATOP cohort. Neurology, 40(10), 1529-1534.

[18] Louis, E. D., Tang, M. X., Cote, L., Alfaro, B., Mejia, H., &Marder, K. (1999). Progression of parkinsonian signs in Parkinson disease. Archives of neurology, 56(3), 334-337.

[19] Hirsch, E. C., Mouatt, A., Faucheux, B., Bonnet, A. M., Javoy-Agid, F., Graybiel, A. M., &Agid, Y. (1992). Dopamine, tremor, and Parkinson's disease. Lancet (London, England), 340(8811), 125–126.

[20] Jellinger, K. A. (1999). Post mortem studies in Parkinson's disease—is it possible to detect brain areas for specific symptoms?. Diagnosis and Treatment of Parkinson's Disease—State of the Art, 1-29.

[21] Elbaz, A., Bower, J. H., Maraganore, D. M., McDonnell, S. K., Peterson, B. J., Ahlskog, J. E., & Rocca, W. A. (2002). Risk tables for parkinsonism and Parkinson's disease. Journal of clinical epidemiology, 55(1), 25-31.

[22] Tanner, C. M., Ottman, R., Goldman, S. M., Ellenberg, J., Chan, P., Mayeux, R., & Langston, J. W. (1999). Parkinson disease in twins: an etiologic study. Jama, 281(4), 341-346.

[23] Elbaz, A., Bower, J. H., Peterson, B. J., Maraganore, D. M., McDonnell, S. K., Ahlskog, J. E., & Rocca, W. A. (2003). Survival study of Parkinson disease in Olmsted county, Minnesota. Archives of Neurology, 60(1), 91-96.

[24] Tripathi, K.D. (2013) Essentials of Medical Pharmacology. 7th Edition, Jaypee Brothers Medical Publishers (P) Ltd., New Delhi, 425-450.

[25] Gowers, W. R. (1887). A manual of diseases of the nervous system. The Journal of Nervous and Mental Disease, 14(2), 123-125.

[26] Dekker, M. C. J., Bonifati, V., & Van Duijn, C. M. (2003). Parkinson's disease: piecing together a genetic jigsaw. Brain, 126(8), 1722-1733.

[27] Pankratz, N., Nichols, W. C., Uniacke, S. K., Halter, C., Rudolph, A., Shults, C., & Parkinson Study Group. (2002). Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations. The American Journal of Human Genetics, 71(1), 124-135.

[28] Scott, W. K., Nance, M. A., Watts, R. L., Hubble, J. P., Koller, W. C., Lyons, K., ... &Pericak-Vance, M. A. (2001). Complete genomic screen in Parkinson disease: evidence for multiple genes. Jama, 286(18), 2239-2244.

[29] Wood, N. W. (1998). Genetic risk factors in Parkinson's disease. Annals of neurology, 44(S1 1), S58-S62.

[30] Golbe, L. I., Di Iorio, G., Bonavita, V., Miller, D. C., &Duvoisin, R. C. (1990). A large kindred with autosomal dominant Parkinson's disease. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society, 27(3), 276-282.

[31] Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., & Nussbaum, R. L. (1997). Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science, 276(5321), 2045-2047.

[32] Spillantini, M. G., Crowther, R. A., Jakes, R., Cairns, N. J., Lantos, P. L., & Goedert, M. (1998). Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neuroscience letters, 251(3), 205-208.

[33] Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., &Riess, O. (1998). AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease. Nature genetics, 18(2), 106-108.

[34] Zarranz, J. J., Alegre, J., Gómez-Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., & de Yebenes, J. G. (2004). The new mutation, E46K, of α-synuclein causes parkinson and Lewy body dementia. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society, 55(2), 164-173.

[35] Farrer, M., Kachergus, J., Forno, L., Lincoln, S., Wang, D. S., Hulihan, M., & Langston, J. W. (2004). Comparison of kindreds with parkinsonism and α-synuclein genomic multiplications. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society, 55(2), 174-179.

[36] Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., & Gwinn-Hardy, K. (2003). [alpha]-synuclein locus triplication causes Parkinson's disease. Science, 302(5646), 841-842.

[37] Ma, Q. L., Chan, P., Yoshii, M., &Uéda, K. (2003). α-Synuclein aggregation and neurodegenerative diseases. Journal of Alzheimer's disease, 5(2), 139-148.

[38] Engelender, S., Kaminsky, Z., Guo, X., Sharp, A. H., Amaravi, R. K., Kleiderlein, J. J., ... & Ross, C. A. (1999). Synphilin-1 associates with α-synuclein and promotes the formation of cytosolic inclusions. Nature genetics, 22(1), 110-114.

[39] Alim, M. A., Hossain, M. S., Arima, K., Takeda, K., Izumiyama, Y., Nakamura, M., Kaji, H., Shinoda, T., Hisanaga, S., & Ueda, K. (2002). Tubulin seeds alpha-synuclein fibril formation. The Journal of biological chemistry, 277(3), 2112–2117

[40] Jensen, P. H., Hager, H., Nielsen, M. S., Højrup, P., Gliemann, J., & Jakes, R. (1999). α-Synuclein binds to tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356. Journal of Biological Chemistry, 274(36), 25481-25489.

[41] Perez, R. G., Waymire, J. C., Lin, E., Liu, J. J., Guo, F., & Zigmond, M. J. (2002). A role for α-synuclein in the

regulation of dopamine biosynthesis. Journal of Neuroscience, 22(8), 3090-3099.

[42] Eliezer, D., Kutluay, E., Bussell Jr, R., & Browne, G. (2001). Conformational properties of α-synuclein in its free and lipid-associated states. Journal of molecular biology, 307(4), 1061-1073.

[43] Conway, K. A., Harper, J. D., & Lansbury, P. T. (1998). Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease. Nature medicine, 4(11), 1318-1320.

[44] Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., & Shimizu, N. (1998). Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. nature, 392(6676), 605-608.

[45] Matsumine, H., Saito, M., Shimoda-Matsubayashi, S., Tanaka, H., Ishikawa, A., Nakagawa-Hattori, Y., & Mizuno, Y. (1997). Localization of a gene for an autosomal recessive form of juvenile Parkinsonism to chromosome 6q25. 2-27. American journal of human genetics, 60(3), 588.

[46] Lücking, C. B., Abbas, N., Dürr, A., Bonifati, V., Bonnet, A. M., De Broucker, T., & Brice, A. (1998). Homozygous deletions in parkin gene in European and North African families with autosomal recessive juvenile parkinsonism. The European Consortium on Genetic Susceptibility in Parkinson's Disease and the French Parkinson's Disease Genetics Study Group. Lancet (London, England), 352(9137), 1355-1356.

[47] Oliveira, S. A., Scott, W. K., Nance, M. A., Watts, R. L., Hubble, J. P., Koller, W. C., ... & Martin, E. R. (2003). Association study of Parkin gene polymorphisms with idiopathic Parkinson disease. Archives of neurology, 60(7), 975-980.

[48] Oliveira, S. A., Scott, W. K., Martin, E. R., Nance, M. A., Watts, R. L., Hubble, J. P., ... & Vance, J. M. (2003). Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society, 53(5), 624-629.

[49] Shimura, H., Schlossmacher, M. G., Hattori, N., Frosch, M. P., Trockenbacher, A., Schneider, R., &Selkoe, D. J. (2001). Ubiquitination of a new form of α-synuclein by parkin from human brain: implications for Parkinson's disease. Science, 293(5528), 263-269.

[50] Imai, Y., Soda, M., Inoue, H., Hattori, N., Mizuno, Y., & Takahashi, R. (2001). An unfolded putative

transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell, 105(7), 891-902.

[51] Zhang, Y., Gao, J., Chung, K. K., Huang, H., Dawson, V. L., & Dawson, T. M. (2000). Parkin functions as an E2-dependent ubiquitin–protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proceedings of the National Academy of Sciences, 97(24), 13354-13359.

[52] Chung, K. K., Zhang, Y. I., Lim, K. L., Tanaka, Y., Huang, H., Gao, J., ... & Dawson, T. M. (2001). Parkin ubiquitinates the α-synuclein–interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nature medicine, 7(10), 1144-1150.

[53] Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey, E., &Polymeropoulos, M. H. (1998). The ubiquitin pathway in Parkinson's disease. Nature, 395(6701), 451-452.

[54] Nishikawa, K., Li, H., Kawamura, R., Osaka, H., Wang, Y. L., Hara, Y., & Wada, K. (2003). Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. Biochemical and biophysical research communications, 304(1), 176-183.

[55] Jones, J. M., Datta, P., Srinivasula, S. M., Ji, W., Gupta, S., Zhang, Z., &Alnemri, E. S. (2003). Loss of Omi mitochondrial protease activity causes the neuromuscular disorder of mnd2 mutant mice. Nature, 425(6959), 721-727.

[56] Kawamoto, Y., Kobayashi, Y., Suzuki, Y., Inoue, H., Tomimoto, H., Akiguchi, I., & Takahashi, R. (2008). Accumulation of HtrA2/Omi in neuronal and glial inclusions in brains with α-synucleinopathies. Journal of Neuropathology & Experimental Neurology, 67(10), 984-993.

[57] Martins, L. M., Morrison, A., Klupsch, K., Fedele, V., Moisoi, N., Teismann, P., & Downward, J. (2004). Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice. Molecular and cellular biology, 24(22), 9848-9862.

[58] Ross, O. A., Soto, A. I., Vilariño-Güell, C., Heckman, M. G., Diehl, N. N., Hulihan, M. M., ... &Farrer, M. J. (2008). Genetic variation of Omi/HtrA2 and Parkinson's disease. Parkinsonism & related disorders, 14(7), 539-543.

[59] imón-Sánchez, J., & Singleton, A. B. (2008). Sequencing analysis of OMI/HTRA2 shows previously

reported pathogenic mutations in neurologically normal controls. Human molecular genetics, 17(13), 1988-1993.

[60] Strauss, K. M., Martins, L. M., Plun-Favreau, H., Marx, F. P., Kautzmann, S., Berg, D., &Krüger, R. (2005). Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Human molecular genetics, 14(15), 2099-2111.

[61] Lücking, C. B., Dürr, A., Bonifati, V., Vaughan, J., De Michele, G., Gasser, T., & Brice, A. (2000). Association between early-onset Parkinson's disease and mutations in the parkin gene. New England Journal of Medicine, 342(21), 1560-1567.

[62] Periquet, M., Latouche, M., Lohmann, E., Rawal, N., De Michele, G., Ricard, S., & Brice, A. (2003). Parkin mutations are frequent in patients with isolated early-onset parkinsonism. Brain, 126(6), 1271-1278.

[63] Hedrich, K., Eskelson, C., Wilmot, B., Marder, K., Harris, J., Garrels, J., & Kramer, P. (2004). Distribution, type, and origin of Parkin mutations: review and case studies. Movement disorders: official journal of the Movement Disorder Society, 19(10), 1146-1157.

[64] Klein, C., Hedrich, K., Wellenbrock, C., Kann, M., Harris, J., Marder, K., & Kramer, P. L. (2003). Frequency of parkin mutations in late-onset Parkinson's disease. Annals of neurology, 54(3), 415-416.

[65] Mata, I. F., Lockhart, P. J., &Farrer, M. J. (2004). Parkin genetics: one model for Parkinson's disease. Human molecular genetics, 13(suppl_1), R127-R133.

[66] Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., & Shimizu, N. (1998). Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. nature, 392(6676), 605-608.

[67] Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M., Harvey, K., Gispert, S., & Wood, N. W. (2004). Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science, 304(5674), 1158-1160.

[68] Valente, E. M., Bentivoglio, A. R., Dixon, P. H., Ferraris, A., Ialongo, T., Frontali, M., & Wood, N. W. (2001). Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. The American Journal of Human Genetics, 68(4), 895-900.

[69] Deas, E., Plun-Favreau, H., & Wood, N. W. (2009). PINK1 function in health

and disease. EMBO molecular medicine, 1(3), 152-165.

[70] Nuytemans, K., Theuns, J., Cruts, M., & Van Broeckhoven, C. (2010). Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Human mutation, 31(7), 763-780.

[71] Cazeneuve, C., Sân, C., Ibrahim, S. A., Mukhtar, M. M., Kheir, M. M., LeGuern, E., & Salih, M. A. (2009). A new complex homozygous large rearrangement of the PINK1 gene in a Sudanese family with early onset Parkinson's disease. Neurogenetics, 10(3), 265-270.

[72] Marongiu, R., Brancati, F., Antonini, A., Ialongo, T., Ceccarini, C., Scarciolla, O., & Valente, E. M. (2007). Whole gene deletion and splicing mutations expand the PINK1 genotypic spectrum. Human mutation, 28(1), 98-98.

[73] Tan, E. K., Yew, K., Chua, E., Puvan, K., Shen, H., Lee, E., & Tan, L. (2006). PINK1 mutations in sporadic early-onset Parkinson's disease. Movement disorders, 21(6), 789-793.

[74] Valente, E. M., Salvi, S., Ialongo, T., Marongiu, R., Elia, A. E., Caputo, V., &Bentivoglio, A. R. (2004). PINK1 mutations are associated with sporadic early-onset parkinsonism. Annals of neurology, 56(3), 336-341.

[75] Ibánez, P., Lesage, S., Lohmann, E., Thobois, S., Michele, G. D., Borg, M., & Brice, A. (2006). Mutational analysis of thePINK1 gene in early-onset parkinsonism in Europe and North Africa. Brain, 129(3), 686-694.

[76] Ephraty, L., Porat, O., Israeli, D., Cohen, O. S., Tunkel, O., Yael, S., &Hassin-Baer, S. (2007). Neuropsychiatric and cognitive features in autosomal-recessive early parkinsonism due to PINK1 mutations. Movement disorders, 22(4), 566-569.

[77] Li, Y., Tomiyama, H., Sato, K., Hatano, Y., Yoshino, H., Atsumi, M., & Hattori, N. (2005). Clinicogenetic study of PINK1 mutations in autosomal recessive early onset parkinsonism. Neurology, 64(11), 1955-1957.

[78] Savettieri, G., Annesi, G., Civitelli, D., Candiano, I. C. C., Salemi, G., Ragonese, P., &Quattrone, A. (2008). Identification of the novel D297fsX318 PINK1 mutation and phenotype variation in a family with early-onset Parkinson's disease. Parkinsonism & related disorders, 14(6), 509-512.

[79] Steinlechner, S., Stahlberg, J., Völkel, B., Djarmati, A., Hagenah, J., Hiller, A., &Lencer, R. (2007). Co-occurrence of affective and schizophrenia spectrum

disorders with PINK1 mutations. Journal of Neurology, Neurosurgery & Psychiatry, 78(5), 532-535.

[80] Funayama, M., Li, Y., Tsoi, T. H., Lam, C. W., Ohi, T., Yazawa, S., & Hattori, N. (2008). Familial Parkinsonism with digenic parkin and PINK1 mutations. Movement disorders: official journal of the Movement Disorder Society, 23(10), 1461-1465.

[81] Bonifati, V., Rizzu, P., Van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., & Heutink, P. (2003). Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science, 299(5604), 256-259.

[82] Tang Tang, B., Xiong, H., Sun, P., Zhang, Y., Wang, D., Hu, Z., & Zhang, Z. (2006). Association of PINK1 and DJ-1 confers digenic inheritance of early-onset Parkinson's disease. Human molecular genetics, 15(11), 1816-1825.

[83] Andres-Mateos, E., Perier, C., Zhang, L., Blanchard-Fillion, B., Greco, T. M., Thomas, B., & Dawson, V. L. (2007). DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proceedings of the National Academy of Sciences, 104(37), 14807-14812.

[84] Canet-Avilés, R. M., Wilson, M. A., Miller, D. W., Ahmad, R., McLendon, C., Bandyopadhyay, S., & Cookson, M. R. (2004). The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proceedings of the National Academy of Sciences, 101(24), 9103-9108.

[85] Funayama, M., Hasegawa, K., Kowa, H., Saito, M., Tsuji, S., & Obata, F. (2002). A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11. 2–q13. 1. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society, 51(3), 296-301.

[86] Zimprich, A., Müller-Myhsok, B., Farrer, M., Leitner, P., Sharma, M., Hulihan, M., & Gasser, T. (2004). The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. The American Journal of Human Genetics, 74(1), 11-19.

[87] Paisán-Ruíz, C., Jain, S., Evans, E. W., Gilks, W. P., Simón, J., Van Der Brug, M., ... & Singleton, A. B. (2004). Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron, 44(4), 595-600.

[88] Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., & Gasser, T. (2004). Mutations in LRRK2

cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron, 44(4), 601-607.

[89] LesageLesage, S., Janin, S., Lohmann, E., Leutenegger, A. L., Leclere, L., Viallet, F., & Brice, A. (2007). LRRK2emph exon 41 mutations in sporadic Parkinson disease in Europeans. Archives of neurology, 64(3), 425-430.

[90] Kay, D. M., Kramer, P., Higgins, D., Zabetian, C. P., & Payami, H. (2005). Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation. Movement disorders: official journal of the Movement Disorder Society, 20(8), 1077-1078.

[91] Latourelle, J. C., Sun, M., Lew, M. F., Suchowersky, O., Klein, C., Golbe, L. I., & Myers, R. H. (2008). The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study. BMC medicine, 6(1), 1-7.

[92] Troiano, A. R., Elbaz, A., Lohmann, E., Belarbi, S., Vidailhet, M., Bonnet, A. M., & Brice, A. (2010). Low disease risk in relatives of north african lrrk2 Parkinson disease patients. Neurology, 75(12), 1118-1119.

[93] Elbaz, A., Levecque, C., Clavel, J., Vidal, J. S., Richard, F., Corrèze, J. R., & Tzourio, C. (2003). S18Y polymorphism in the UCH-L1 gene and Parkinson's disease: Evidence for an age-dependent relationship. Movement disorders: official journal of the Movement Disorder Society, 18(2), 130-137.

[94] Ishihara, L., Warren, L., Gibson, R., Amouri, R., Lesage, S., Dürr, A., & Hentati, F. (2006). Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations. Archives of neurology, 63(9), 1250-1254.

[95] Lesage, S., Belarbi, S., Troiano, A., Condroyer, C., Hecham, N., Pollak, P., & Brice, A. (2008). Is the common LRRK2 G2019S mutation related to dyskinesias in North African Parkinson disease?. Neurology, 71(19), 1550-1552.

[96] Lesage, S., Dürr, A., Tazir, M., Lohmann, E., Leutenegger, A. L., Janin, S., & Brice, A. (2006). LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. New England Journal of Medicine, 354(4), 422-423.

[97] Paisan-Ruiz, C., Lang, A. E., Kawarai, T., Sato, C., Salehi-Rad, S., Fisman, G. K., & Rogaeva, E. (2005). LRRK2 gene in Parkinson disease: mutation analysis and case control association study. Neurology, 65(5), 696-700.